Conference Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 243 - Operational Considerations in Clinical Trials
Type: Contributed
Date/Time: Tuesday, August 9, 2022 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #323082
Title: Statistical Power of Survival Trials Weakened by COVID-19 Pandemic
Author(s): Ping Xu* and Gregory T Golm
Companies: Merck & Co. and Merck & Co.
Keywords: Competing Risk; Survival Trials; Simulations; Number Needed to Treat
Abstract:

The U.S. Food and Drug Administration (FDA) has issued guidance delineating general considerations for conducting clinical trials of investigational drugs during the COVID-19 pandemic. FDA recommends that sponsors should consider how to analyze data from participants who are missing endpoint ascertainment or for whom the investigational product was interrupted because of SARS-CoV-2 infection. Since the pandemic's beginning, it has been globally observed that competing risks, such as death due to COVID-19, can occur before the event of interest in randomized clinical trials where the primary endpoint of a trial is survival time. Consequently, the statistical power over the originally planned sample size warrants careful re-assessment to overcome the loss of information from the impact of COVID-19. In this study, we have performed simulations to assess the extent of the impact of COVID-19 on the statistical power and number needed to treat (NNT) in survival trials in the context of competing risks. We provide practical statistical considerations for planning a trial to ensure appropriate statistical power and NNT to detect the clinical efficacy of investigational drugs in clinical t


Authors who are presenting talks have a * after their name.

Back to the full JSM 2022 program